University of Texas Hlth Sci Ctr Houston
INTERNAL MEDICINE/MEDICINE
Houston · United States
NIH R01 · 2025
PROJECT SUMMARY The goal of this proposal is to develop a targeted therapy for treatment of metastatic castration-resistant prostate cancer (mCRPC). There is currently no cure for this disease and available therapies leave significant room for improvement based on dismal survival rates. Prostate-specific membrane antigen (PSMA) is a clinically validated molecular target for diagnostic and therapeutic purposes based on its significant overexpression in PCa tissue compared to normal cells. Glutamate-ureido-based small molecules have exceptional affinity for PSMA and have been labeled with radionuclides to enable targeted tumor detection and therapy. The small molecule 177Lu- PSMA-617…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.